File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/ajg.2011.253
- Scopus: eid_2-s2.0-80053894414
- PMID: 21826112
- WOS: WOS:000295926600005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment
Title | Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment |
---|---|
Authors | |
Issue Date | 2011 |
Publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html |
Citation | American Journal Of Gastroenterology, 2011, v. 106 n. 10, p. 1766-1773 How to Cite? |
Abstract | Objectives: The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients receiving oral antiviral therapy is controversial. We aimed to determine the HBsAg response in chronic hepatitis B patients treated with entecavir 0.5 mg daily for 2 years. Methods: A total of 166 patients were included. Liver biochemistry, hepatitis B virus (HBV) serological markers, HBV DNA, and quantitative HBsAg levels were performed at baseline, year 1, and year 2 after commencing entecavir. Additional HBsAg levels were measured at 12 and 24 weeks in patients with available sera. Results: In all, 68 patients were hepatitis B e-antigen (HBeAg) positive. Age, HBV DNA, and alanine aminotransferase (ALT) were significantly correlated with HBsAg levels at baseline (r=-0.429, 0.607, and 0.254, respectively, all P<0.05). The correlation with HBV DNA and ALT levels was reduced by entecavir treatment, and was lost after 2 years of treatment. There was an overall decline in HBsAg levels from baseline to year 1 to year 2 (3,377.4 vs. 2,316.5 vs. 1,903.0 IU/ml, respectively, P<0.001). However, at year 2, 102 patients (61%) had no significant changes (<0.5 log difference), 50 (30%) had significant decline (≥0.5 log decrease), whereas 14 (9%) had significant increase (0.5 log increase). Of the patients, 151 (91%) had undetectable HBV DNA; 25 (37%) underwent HBeAg seroconversion. Neither HBsAg at baseline nor early decline at weeks 12 or 24 was predictive of HBeAg seroconversion at 2 years. Conclusions: Despite HBV DNA suppression, the majority did not show significant decline in HBsAg levels. Early decline of HBsAg levels at 12/24 weeks was not associated with HBV DNA suppression or HBeAg seroconversion. © 2011 by the American College of Gastroenterology. |
Persistent Identifier | http://hdl.handle.net/10722/142389 |
ISSN | 2023 Impact Factor: 8.0 2023 SCImago Journal Rankings: 2.391 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fung, J | en_HK |
dc.contributor.author | Lai, CL | en_HK |
dc.contributor.author | Young, J | en_HK |
dc.contributor.author | Wong, DKH | en_HK |
dc.contributor.author | Yuen, J | en_HK |
dc.contributor.author | Seto, WK | en_HK |
dc.contributor.author | Yuen, MF | en_HK |
dc.date.accessioned | 2011-10-28T02:44:56Z | - |
dc.date.available | 2011-10-28T02:44:56Z | - |
dc.date.issued | 2011 | en_HK |
dc.identifier.citation | American Journal Of Gastroenterology, 2011, v. 106 n. 10, p. 1766-1773 | en_HK |
dc.identifier.issn | 0002-9270 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/142389 | - |
dc.description.abstract | Objectives: The role of quantitative hepatitis B surface antigen (HBsAg) levels in patients receiving oral antiviral therapy is controversial. We aimed to determine the HBsAg response in chronic hepatitis B patients treated with entecavir 0.5 mg daily for 2 years. Methods: A total of 166 patients were included. Liver biochemistry, hepatitis B virus (HBV) serological markers, HBV DNA, and quantitative HBsAg levels were performed at baseline, year 1, and year 2 after commencing entecavir. Additional HBsAg levels were measured at 12 and 24 weeks in patients with available sera. Results: In all, 68 patients were hepatitis B e-antigen (HBeAg) positive. Age, HBV DNA, and alanine aminotransferase (ALT) were significantly correlated with HBsAg levels at baseline (r=-0.429, 0.607, and 0.254, respectively, all P<0.05). The correlation with HBV DNA and ALT levels was reduced by entecavir treatment, and was lost after 2 years of treatment. There was an overall decline in HBsAg levels from baseline to year 1 to year 2 (3,377.4 vs. 2,316.5 vs. 1,903.0 IU/ml, respectively, P<0.001). However, at year 2, 102 patients (61%) had no significant changes (<0.5 log difference), 50 (30%) had significant decline (≥0.5 log decrease), whereas 14 (9%) had significant increase (0.5 log increase). Of the patients, 151 (91%) had undetectable HBV DNA; 25 (37%) underwent HBeAg seroconversion. Neither HBsAg at baseline nor early decline at weeks 12 or 24 was predictive of HBeAg seroconversion at 2 years. Conclusions: Despite HBV DNA suppression, the majority did not show significant decline in HBsAg levels. Early decline of HBsAg levels at 12/24 weeks was not associated with HBV DNA suppression or HBeAg seroconversion. © 2011 by the American College of Gastroenterology. | en_HK |
dc.language | eng | en_US |
dc.publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html | en_HK |
dc.relation.ispartof | American Journal of Gastroenterology | en_HK |
dc.subject.mesh | Antiviral Agents - administration and dosage - therapeutic use | - |
dc.subject.mesh | Guanine - administration and dosage - analogs and derivatives - therapeutic use | - |
dc.subject.mesh | Hepatitis B Surface Antigens - blood | - |
dc.subject.mesh | Hepatitis B virus - genetics - immunology - isolation and purification | - |
dc.subject.mesh | Hepatitis B, Chronic - drug therapy - enzymology - immunology | - |
dc.title | Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0002-9270&volume=106&issue=10&spage=1766&epage=1773&date=2011&atitle=Quantitative+Hepatitis+B+Surface+Antigen+Levels+in+Patients+With+Chronic+Hepatitis+B+After+2+Years+of+Entecavir+Treatment | en_US |
dc.identifier.email | Fung, J: jfung@sicklehut.com | en_HK |
dc.identifier.email | Lai, CL: hrmelcl@hku.hk | en_HK |
dc.identifier.email | Wong, DKH: danywong@hku.hk | en_HK |
dc.identifier.email | Seto, WK: wkseto2@hku.hk | en_HK |
dc.identifier.email | Yuen, MF: mfyuen@hku.hk | en_HK |
dc.identifier.authority | Fung, J=rp00518 | en_HK |
dc.identifier.authority | Lai, CL=rp00314 | en_HK |
dc.identifier.authority | Wong, DKH=rp00492 | en_HK |
dc.identifier.authority | Seto, WK=rp01659 | en_HK |
dc.identifier.authority | Yuen, MF=rp00479 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1038/ajg.2011.253 | en_HK |
dc.identifier.pmid | 21826112 | - |
dc.identifier.scopus | eid_2-s2.0-80053894414 | en_HK |
dc.identifier.hkuros | 196659 | en_US |
dc.identifier.hkuros | 213672 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-80053894414&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 106 | en_HK |
dc.identifier.issue | 10 | en_HK |
dc.identifier.spage | 1766 | en_HK |
dc.identifier.epage | 1773 | en_HK |
dc.identifier.isi | WOS:000295926600005 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Fung, J=23091109300 | en_HK |
dc.identifier.scopusauthorid | Lai, CL=7403086396 | en_HK |
dc.identifier.scopusauthorid | Young, J=16949957200 | en_HK |
dc.identifier.scopusauthorid | Wong, DKH=7401535819 | en_HK |
dc.identifier.scopusauthorid | Yuen, J=7102620480 | en_HK |
dc.identifier.scopusauthorid | Seto, WK=23390675900 | en_HK |
dc.identifier.scopusauthorid | Yuen, MF=7102031955 | en_HK |
dc.identifier.issnl | 0002-9270 | - |